logo-loader
viewSeres Therapeutics

Seres Therapeutics shares falter on $60M secondary public offering

The microbiome drugmaker will offer 26.6 million shares at a price of $2.25 per share

Pills
Seres Therapeutics’ drug pipeline includes SER-287, an Ulcerative Colitis treatment

Seres Therapeutics Inc (NASDAQ:MCRB) shares were slumping after the company announced a $60 million secondary public offering of stock.

The microbiome drugmaker will offer 26.6 million shares at a price of $2.25 per share, 31% cheaper than its Thursday close.

Shares dipped 24% to $2.14 Friday as investors typically consider secondary offerings to be dilutive.

READ: Seres Therapeutics shares pop on new cancer research collaboration with AstraZeneca

The Cambirdge, Massachusetts company plans to use the proceeds to further develop its drug pipeline and for other corporate and working capital purposes.

Seres Therapeutics’ drug pipeline includes SER-287, an Ulcerative Colitis treatment, and SER-401, a treatment for melanoma patients undergoing immunotherapy.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Seres Therapeutics

Price: 22.7 USD

NASDAQ:MCRB
Market: NASDAQ
Market Cap: $1.73 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Alpha Growth PLC’s Danny Swick and Austin King describe the BlackOak Alpha...

Alpha Growth PLC (LON: ALGW) Chief Operations Officer Danny Swick and Investor Relations Officer Austin King joined Steve Darling from Proactive with news the company has started their BlackOak Alpha Growth Fund which is their life settlement investment fund geared toward U.S. investors. Both...

6 hours, 12 minutes ago

2 min read